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Non-communicable diseases (NCDs) have reached pandemic levels globally and pose a major threat to social and economic
development worldwide. The discipline of epidemiology has done much to bring this issue to the forefront of global
health. Epidemiological approaches have broadened our understanding of the impact of NCDs in widening socioeconomic
disparities. Over a number of decades, this discipline has also contributed to the development of many preventive measures
and treatments of known efficacy and safety. However, epidemiology also has a critical role to play in better translating these
discoveries into practice, through the new science of implementation. As we strive to achieve the “25 by 25” goal of a 25%
reduction in premature mortality from common NCDs by 2025, the discipline of epidemiology will need to continuously
evolve to remain an essential tool for public health action.
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In November 2009, the Economist published an article ac-
cusing the World Health Organization (WHO) of ‘mission
creep’ and ‘nannying’ in response to their efforts to raise
global attention to the perils associated with obesity, smok-
ing and other ‘non-infectious ailments’ [1]. Branding such
conditions as ‘lifestyle diseases’ occurring as a consequence
of personal choice, the magazine cajoled multilateral agencies
to avoid focusing on conditions associated with affluence and
instead concentrate efforts on infectious diseases affecting
developing countries. Fast forward to September 2011 and
the UN High Level Meeting on Non-communicable Diseases
(NCDs) was held in New York – only the second time the
UN has convened such a meeting relating to a global health
issue, the first being in response to HIV/AIDS in 2001. The en-
suing Political Declaration recognised the global threat that
NCDs pose, identifying these conditions as one of the major
challenges facing social and economic development globally
and an important contributor to rising inequalities both within
and between countries [2]. Subsequently at the 65th World
Health Assembly in 2012, WHO member states made a
commitment to reduce premature deaths from a group of spe-
cified NCDs [cardiovascular diseases (CVD), diabetes, cancer
and chronic respiratory diseases] by 25% by the year 2025
(‘25 × 25’ goal). This was followed by adoption of a global mon-
itoring frameworkof nine voluntary globalNCDtargets that fo-
cuses on risk factors such as tobacco and alcohol use, physical
inactivity, high salt intake, high blood pressure, diabetes and
obesity, as well as the availability of basic technologies andmed-
icines for the prevention and treatment of major NCDs [3].
This wider acceptance of NCDs as an important global
health threat owes much to the discipline of epidemiology –
that branch of medical science dealing with the incidence, dis-
tribution and opportunities for control of diseases and their
determinants. Particularly noteworthy is the pivotal work
of the Global Burden of Disease (GBD) consortium. A land-
mark publication in 2001 provided a comprehensive global
and regional assessment of morbidity and mortality asso-
ciated with diseases and their risk factors, using the new
and subsequently widely-used metric of disability-adjusted
life years (DALYs) [4]. Particularly important were the
comparisons made between estimates of disease burden in
1990 and 2001, which highlighted the rapid epidemiological
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transition occurring in most low and middle income countries
(LMIC) towards NCDs becoming leading causes of morbidity
and premature mortality. Despite limitations reflecting avail-
able primary data (an ongoing concern in many countries
that highlights the importance of high quality surveillance
data) and concerns raised about the methodology utilised
for estimating DALYs, this work laid the foundations for
the future acknowledgement of NCDs as a true global health
threat. More recent data from the GBD group have con-
firmed that the risk factors defined by the voluntary global
NCD targets are large contributors to disease burden [5].
Epidemiology has also done much to explode the myth of
NCDs being the preserve of the affluent. As early as in
the 1970s, Marmot et al. posited a reversal of the socio-
economic gradient in the association with CVD in the UK,
demonstrating that the heart disease mortality rate ratio
among groups of higher v. lower socioeconomic status chan-
ged from 1.2 to 0.9 between 1949–1953 and 1970–1972 [6].
While it is difficult to determine the extent to which a simi-
lar reversal has occurred or is occurring in LMIC, there is
incontrovertible evidence of increasingly adverse NCD
risk factor profiles and high NCD prevalence among poorer
communities within such countries. There is also strong evi-
dence of accompanying disadvantage in receipt of appropri-
ate treatments. For example, a recent cross-sectional study
involving 17 countries showed that in both upper and lower
middle-income nations, the prevalence of hypertension was
similar in urban and rural populations [7]. While the preva-
lence of hypertension was lower in rural v. urban communi-
ties in low income countries (mainly sub-Saharan Africa),
almost one-third of the rural adult population aged between
35 and 70 years was affected. Awareness, treatment and
control of hypertension were substantially lower in rural
compared with urban populations in low-middle and low in-
come countries. Other data from this study demonstrate
substantially lower use of appropriate secondary prevention
drugs among people with established CVD in rural com-
pared to urban populations in developing economies [8].
High quality epidemiological data have been pivotal in
establishing the risk factors and likely causal determinants
of NCDs, many of which are the focus of the voluntary tar-
gets for the ‘25 × 25’ goal. A key difference between infec-
tious disease epidemiology and that for most NCDs
relates to the multiple pathways of causality associated
with the latter. Such recognition underscored the need for
the very large studies to establish often moderate associa-
tions with individual risk factors. An early and often cited ex-
ample of this is the establishment of cigarette smoking as a
likely causal risk factor for lung cancer, through the seminal
case control and cohort studies conducted by Doll and Hill
in the 1950s [9, 10]. More than half a century later, while
epidemiological data show us that smoking rates have sub-
stantially declined over the last few decades in most devel-
oped economies, they demonstrate the opposite is true of
many LMIC. In fact, it is estimated that over 70% of
tobacco-related deaths will occur in LMIC by the year
2020 [11]. A recent study indicated that if current trends
continue, tobacco control targets will not be achieved in
many LMIC by 2025, and indeed tobacco use will increase
in several [12].
In addition to collection and analyses of observational data,
the discipline of epidemiology has provided the gold standard
methodology for establishing the role of drugs and devices to
prevent and treat diseases. While the first examples of the
archetypal modern double-blind, placebo-controlled rando-
mised controlled trial were applied to infectious diseases,
NCDs have particularly benefited from an explosion of thera-
peutic developments, which in turn have been evaluated
rigorously in large scale randomised trials to provide reliable
evidence about efficacy and safety. This has led to the avail-
ability of a large arsenal of safe, efficacious, and in many
cases, increasingly affordable treatments. In turn, epidemio-
logical methods can provide estimates about the benefits
accrued from the use of therapies at a population level. For
example, a number of modelling studies have attributed the
decline in coronary heart disease incidence and mortality
observed in developed countries over recent decades to a
combination in reduced population-level risk (especially as a
result of a decline in smoking rates), as well success with
treatments, both for the acute management of coronary
events as well as long-term secondary prevention [13].
However, despite the availability of treatments of proven
safety and efficacy, large evidence-practice gaps exist world-
wide. This has led to the development of what might be
described as one of the newer branches of epidemiology,
namely implementation science. This discipline is essentially
concerned with knowledge translation, developing and pro-
viding evidence for strategies to increase the adoption and
sustainable scale-up of evidence-based healthcare (i.e. going
beyond ‘does it work?’). Fundamentally, implementation sci-
ence is about changing behaviour, with an understanding
that people (policy makers, healthcare administrators, health-
care providers, patients, community members) operate and
make decisions in complex environments. To achieve afford-
able and effective healthcare the local social, cultural, physical
(institutions, workforce and resources) and political context
all need to be evaluated and navigated. How people will re-
spond is generally also informed by their own experiences,
values, norms and learning. Implementation science is there-
fore characterised by the need to extend the traditional
boundaries of epidemiology, and for epidemiologists to col-
laborate widely with professionals from a range of other dis-
ciplines including social science, health economics and
various strands of health systems research. Implementation
science needs to incorporate a range of both quantitative
and qualitative research methodologies that might not only
address a specific implementation problem, but also further
generalisable knowledge about changing behaviour in the
healthcare context. Many would argue that given the limited
research funding available to address the needs of LMIC,
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implementation science deserves some priority in terms of
most rapidly realising the health benefits of existing medical
knowledge.
Like all branches of science, epidemiology continues to
evolve. Today, a scientist involved in the practice of epidemi-
ology may introduce her or himself as a ‘risk factor epidemi-
ologist’, ‘environmental epidemiologist’, ‘genetic
epidemiologist’, ‘life-course epidemiologist’, ‘clinical trialist’,
or ‘implementation scientist’, amongst many other such
titles, with or without a particular disease focus. All such fla-
vours of epidemiology are crucial to address the NCD
agenda and a useful unifying conceptual approach is to con-
sider epidemiology as the basic science of public health,
where causal inference remains the central and fundamental
objective. This is regardless of whether epidemiological
approaches are being used in the search for new drivers
of disease burden or the discovery of effective, affordable
and accessible population-based or clinical approaches to
combat these conditions. Most importantly, as has been
demonstrated in its use in so many of its forms in addressing
the enormous global challenge of preventing and controlling
NCDs, epidemiology must continue to act as a critical scien-
tific tool for public health action. For example, a recent
modelling study suggests that continuation of current trends
in risk factor levels will lead to a relative increase in prema-
ture CVD mortality globally by 2025, with a decrease only
observed in high income countries [14]. These analyses indi-
cate that in many regions of the world, the ‘25 × 25’ goal will
not be met even if all risk factor targets are met. Such epi-
demiological data highlight the enormous challenge ahead
and the likelihood of failure without an immediate and com-
prehensive multisectoral response across the globe.
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